Aparna Group forays into pharma business; Receives USFDA clearance for manufacturing unit
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The company has received Form 483 with three observations
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated